Pharmafile Logo
Pharmafocus logo
Advanced Search

Mylan

Showing 15 posts of 123 posts found.

perrigo

Perrigo rejects $26 billion hostile Mylan takeover bid

November 13, 2015
Medical Communications, Sales and Marketing Mylan, Perrigo, mergers and acquisitions

Perrigo has rejected Mylan’s hostile $26 billion bid after a 60% majority of shareholders were unconvinced by the terms by …

News

Mylan appoints a global commercial lead for OTC business

November 3, 2015
Manufacturing and Production Mylan, OTC, Ranjan Ray Chaudhuri, over the counter

Mylan has appointed Ranjan Ray Chaudhuri as its new global commercial lead for the company’s over-the-counter (OTC) business. Chaudhuri will …

Appointment
Pharma pill manufacturing

FDA hits Mylan’s Indian plants with warning letter

August 20, 2015
Manufacturing and Production Contamination, FDA, Mylan, Pfizer, manufacturing, production

The FDA has served Mylan with a warning letter citing contamination at three of its manufacturing facilities in India. Inspections …

News
Teva image

Teva ‘to increase Mylan bid to $43bn’

July 7, 2015
Sales and Marketing M&A, MA, Mylan, Teva, generics

Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …

News
Perrigo image

Perrigo buys OTC products from GSK

June 3, 2015
Sales and Marketing GSK, GlaxoSmithKline, Mylan, Perrigo, Teva, brett wells

In an all-cash move with no financial details disclosed Perrigo is buying a portfolio of leading over-the-counter products from GlaxoSmithKline. …

News
Mylan image

Mylan tells Teva to ‘stop playing games’ and make firm bid

June 2, 2015
Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics

Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …

News
Teva image

Teva forges ahead with Mylan pursuit

May 6, 2015
Sales and Marketing Mylan, Perrigo, Teva, generics

Teva has reinforced its commitment to buy Mylan despite previous rejection and only days after Mylan upped its own bid …

News
Perrigo image

Perrigo bats away raised Mylan bid

April 30, 2015
Sales and Marketing Mylan, Perrigo, Teva, Vigodman, merger

Perrigo has rejected an updated $34.1 billion takeover bid from Mylan, whilst Teva has also written an open letter in …

News
teva_copy

M&A drama continues as Mylan rejects Teva

April 28, 2015
Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers

Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …

News
Teva image

Teva faces $512m fine in generic Provigil row

April 22, 2015
Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil

Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …

News
Teva image

Teva moves to buy Mylan

April 21, 2015
Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger

Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …

News
Perrigo image

Mylan in huge $29 billion bid for Perrigo

April 9, 2015
Abbott, Mylan, OTC, Perrigo, Shire

Mylan has offered to pay the over-the-counter (OTC) drug specialist Perrigo $28 billion to acquire its business. The proposed deal …

News
Mylan image

Mylan buys into women’s health

February 3, 2015
Sales and Marketing Abbott, FDA, India, Mylan, famy care, female, women

Mylan is to acquire a number of women’s healthcare companies from Indian-based Famy Care that will build upon its 2008 …

News
GSK image

GSK-Novartis mega-deal signed-off by EC

January 29, 2015
Research and Development, Sales and Marketing Abbott, GSK, Mylan, Novartis, acquisition, etc, merger

The European Commission has approved a GSK-Novartis M&A deal, in which GSK will purchase Novartis’ vaccines unit and Novartis will …

News
Teva image

US Supreme Court backs Teva in Copaxone patent case

January 28, 2015
Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva

Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024